Kristine M. Ball
CIK: 0001266163
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Oct 14, 2026ELVN
Enliven Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
23.4K shares- - Jun 2, 2026ORKA
Oruka Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
9.1K shares- - Jun 2, 2025ORKA
Oruka Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
17.5K shares-
1-3 of 3 transactions
About BALL KRISTINE M
BALL KRISTINE M (SEC CIK 0001266163) files insider reports with the SEC as Director of Enliven Therapeutics, Inc. (ELVN) and Director of Oruka Therapeutics, Inc. (ORKA).
Signal8 holds 5 ownership filings by BALL KRISTINE M (2 Form 3, 3 Form 4), filed between Sep 6, 2024 and Oct 16, 2026. Those filings report 3 transactions, from Jun 2, 2025 to Oct 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BALL KRISTINE M's filings is in BURLINGAME, CA.
Recent filings by BALL KRISTINE M
Other insiders filing for Enliven Therapeutics, Inc. (ELVN)
- Kunkel Lori Anne, Officer
- Hohl Benjamin, CHIEF FINANCIAL OFFICER
- Collins Helen Louise, CHIEF MEDICAL OFFICER
- Garland J. Scott, Director
- Derynck Mika K, Director
- ORBIMED ADVISORS LLC, 10% Owner